Table 2.

CTCAE of any grade reported in ≥20% of patients overall

	Patients with AEs, N (%)
	AZD4877 dose
	10 mg (N = 3)	15 mg (N = 3)	20 mg (N = 6)	25 mg (N = 6)	Total (N = 18)
Fatigue	1 (33)	1 (33)	2 (33)	3 (50)	7 (39)
Nausea	2 (67)	1 (33)	1 (17)	3 (50)	7 (39)
Pyrexia	0	3 (100)	2 (33)	1 (17)	6 (33)
Diarrhea	2 (67)	1 (33)	0	2 (33)	5 (28)
Dizziness	2 (67)	0	3 (50)	0	5 (28)
Rash	0	3 (100)	2 (33)	0	5 (28)
Constipation	1 (33)	0	1 (17)	2 (33)	4 (22)
Nasopharyngitis	0	0	2 (33)	2 (33)	4 (22)
Insomnia	1 (33)	0	2 (33)	1 (17)	4 (22)